RizaCare infusion, manufactured by Novartis Pharma, contains L-lysine hydrochloride and L-arginine hydrochloride, available as a 1L 1 bag injectable drug (YJ code: 3253416A1020). This solution is indicated for the reduction of renal radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.
RizaCare infusion
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).